A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant; Paroxetine

Criteria

Inclusion Criteria:

• Patients with Generalized Social Anxiety Disorder as the primary diagnosis.

• If female, must commit to consistent and correct use of an acceptable method of birth control.

Exclusion Criteria:

• Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.

• Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.

• Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.

• Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.

• Patients with an unstable medical disorder.

• Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.

• Patients who are taking other psychoactive medications.